Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023 at 16:00 PM EDT
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates for hypercholesterolemia and metabolic diseases.
